What is WO2010 029082 for alpelisib?
WO2010 029082 is a patent publication that covers subject matter related to alpelisib (the PI3K-alpha inhibitor sold as Piqray). Patent publications with a WO number typically describe the underlying chemical compounds, preparation methods, and/or medical uses claimed by the applicant for that drug candidate.
Who filed WO2010 029082 and what does it claim?
The provided information does not include the assignee/applicant name, claim focus (compound vs. method vs. use), or the specific technical details inside WO2010 029082. To identify what exactly is claimed, you would need the patent record text for WO2010 029082 (title, applicant, abstract, and independent claims).
How does WO2010 029082 relate to patents on alpelisib’s formulation and uses?
WO publications for a drug usually cover early-stage invention content (often chemical structures and synthesis). Separate later patent families often cover:
- specific formulations or dosing regimens,
- crystal forms/solid-state properties,
- combinations (e.g., with fulvestrant, etc.),
- manufacturing processes,
- and regulatory exclusivities.
WO2010 029082 may be part of the “core” IP around the active molecule, but the exact relationship depends on the family and what later patents claim.
When would a patent like WO2010 029082 expire?
A publication like WO2010 029082 generally does not map 1:1 to a single expiry date without:
- the priority date (the first filing date),
- whether patents in the family were granted in specific jurisdictions,
- and whether any patent term adjustments or extensions apply.
If you share the priority date or the applicant, I can help estimate the likely timeline in broad terms.
Where can you look up WO2010 029082 in a patent database?
You can usually find the full record (PDF, bibliographic data, and claim language) by searching:
- WIPO PATENTSCOPE (search by WO number), or
- Google Patents (enter “WO2010 029082”)
If you want, paste the abstract or the assignee from the WO2010 029082 record, and I’ll translate what it covers and how it connects to alpelisib.